NASDAQ:LEXX

Lexaria Bioscience News Headlines

$6.77
-0.62 (-8.39 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.51
$7.29
50-Day Range
$5.40
$8.44
52-Week Range
$3.98
$12.50
Volume674,410 shs
Average Volume2.88 million shs
Market Capitalization$34.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Lexaria Bioscience (NASDAQ LEXX) News Headlines Today

SourceHeadline
Lexaria Bioscience Corp.: Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing StrategyLexaria Bioscience Corp.: Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
finanznachrichten.de - July 24 at 11:25 PM
Lexaria Bioscience Corp.: Lexarias DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3Lexaria Bioscience Corp.: Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
finanznachrichten.de - July 22 at 11:36 PM
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing StrategyLexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
finance.yahoo.com - July 22 at 8:35 AM
Lexarias DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
finance.yahoo.com - July 21 at 9:12 AM
Lexaria Bioscience Corp.: Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canadas National Research CouncilLexaria Bioscience Corp.: Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
finanznachrichten.de - July 16 at 7:03 PM
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital MarketsLexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
finance.yahoo.com - July 5 at 12:57 PM
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
finance.yahoo.com - June 17 at 12:30 PM
Lexaria Bioscience Corp.: Lexaria Provides Progress Report on Six R&D ProgramsLexaria Bioscience Corp.: Lexaria Provides Progress Report on Six R&D Programs
finanznachrichten.de - June 9 at 8:59 AM
Lexaria Provides Progress Report on Six R&D ProgramsLexaria Provides Progress Report on Six R&D Programs
finance.yahoo.com - June 9 at 8:59 AM
Lexaria Bioscience Corp.: Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1Lexaria Bioscience Corp.: Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
finanznachrichten.de - June 7 at 9:02 AM
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
finance.yahoo.com - June 7 at 9:02 AM
Lexaria Bioscience on Drug Delivery Technology and its Patented DehydraTECHLexaria Bioscience on Drug Delivery Technology and its Patented DehydraTECH
benzinga.com - June 3 at 12:31 PM
Lexarias DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 VirusLexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
finance.yahoo.com - June 3 at 7:30 AM
Lexarias Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results EverLexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
finance.yahoo.com - May 20 at 7:28 AM
Lexaria Bioscience Corp.: Lexaria Strengthens Its International Patent Portfolio to 19 Patents GrantedLexaria Bioscience Corp.: Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
finanznachrichten.de - May 12 at 7:57 AM
Lexaria Strengthens Its International Patent Portfolio to 19 Patents GrantedLexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
finance.yahoo.com - May 12 at 7:57 AM
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ETLexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET
finance.yahoo.com - May 7 at 1:45 PM
Lexaria Bioscience Corp. Discusses Potential of DehydraTECH(TM) CBD for Revolutionary Hypertension Solution with The Stock Day PodcastLexaria Bioscience Corp. Discusses Potential of DehydraTECH(TM) CBD for Revolutionary Hypertension Solution with The Stock Day Podcast
finance.yahoo.com - May 7 at 1:45 PM
Lexaria Bioscience Corp.: Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1Lexaria Bioscience Corp.: Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
finanznachrichten.de - May 6 at 7:38 AM
BTV Explores Investment Options in Life SciencesBTV Explores Investment Options in Life Sciences
finance.yahoo.com - May 6 at 7:38 AM
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
finance.yahoo.com - May 6 at 7:38 AM
Lexaria Bioscience Corp., Proprietary Drug Delivery Technology, CEO Clip VideoLexaria Bioscience Corp., Proprietary Drug Delivery Technology, CEO Clip Video
finance.yahoo.com - April 27 at 5:37 PM
Lexarias Dehydration Technology Makes CBD Treatment More EfficientLexaria's Dehydration Technology Makes CBD Treatment More Efficient
seekingalpha.com - April 24 at 9:52 AM
We Think Lexaria Bioscience (NASDAQ:LEXX) Can Afford To Drive Business GrowthWe Think Lexaria Bioscience (NASDAQ:LEXX) Can Afford To Drive Business Growth
nasdaq.com - April 23 at 11:30 PM
Lexaria Commences Human Clinical Hypertension StudyLexaria Commences Human Clinical Hypertension Study
finance.yahoo.com - April 22 at 8:01 AM
Were Hopeful That Lexaria Bioscience (NASDAQ:LEXX) Will Use Its Cash WiselyWe're Hopeful That Lexaria Bioscience (NASDAQ:LEXX) Will Use Its Cash Wisely
finance.yahoo.com - April 20 at 1:30 PM
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOsThe Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
markets.businessinsider.com - April 16 at 8:41 AM
NA Proactive news snapshot: Lexaria Bioscience, New Pacific Metals, HempFusion Wellness, Gevo, Information Services Corporation UPDATENA Proactive news snapshot: Lexaria Bioscience, New Pacific Metals, HempFusion Wellness, Gevo, Information Services Corporation UPDATE
proactiveinvestors.com - April 15 at 7:11 PM
Lexaria Bioscience: Turning the Tide on HypertensionLexaria Bioscience: Turning the Tide on Hypertension
finance.yahoo.com - April 15 at 9:10 AM
Lexarias DehydraTECHTM Technology Utilized in Amaris "Everyday Calm," Named a Top CBD Product Pick by New Hope NetworkLexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network
finance.yahoo.com - April 14 at 9:57 AM
Lexaria Is Expanding CBD Use Beyond Medical Applications into $2.65 Billion MarketplaceLexaria Is Expanding CBD Use Beyond Medical Applications into $2.65 Billion Marketplace
finance.yahoo.com - April 8 at 9:41 AM
Lexaria Bioscience to evaluate DehydraTECH in four drug marketsLexaria Bioscience to evaluate DehydraTECH in four drug markets
proactiveinvestors.com - April 6 at 12:34 PM
Lexaria Bioscience Corp.: Lexaria to Evaluate DehydraTECH in Multiple New MarketsLexaria Bioscience Corp.: Lexaria to Evaluate DehydraTECH in Multiple New Markets
finanznachrichten.de - April 6 at 7:34 AM
Lexaria to Evaluate DehydraTECH(TM) in Multiple New MarketsLexaria to Evaluate DehydraTECH(TM) in Multiple New Markets
finance.yahoo.com - April 6 at 7:34 AM
Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD BeveragesLexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD Beverages
finance.yahoo.com - March 24 at 9:06 AM
Lexaria to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021 at 9:45 AM ETLexaria to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021 at 9:45 AM ET
finance.yahoo.com - March 23 at 8:03 AM
Lexaria Bioscience reports progress in two antiviral drug studies in its 2021 applied R&D programLexaria Bioscience reports progress in two antiviral drug studies in its 2021 applied R&D program
proactiveinvestors.com - March 17 at 2:32 PM
Lexarias Antiviral Drug Evaluation Program ProgressingLexaria's Antiviral Drug Evaluation Program Progressing
finance.yahoo.com - March 16 at 8:47 AM
Lexaria Bioscience Corp.: Rapid Progress in Hypertension Studies by LexariaLexaria Bioscience Corp.: Rapid Progress in Hypertension Studies by Lexaria
finanznachrichten.de - March 15 at 7:25 AM
Rapid Progress in Hypertension Studies by LexariaRapid Progress in Hypertension Studies by Lexaria
finance.yahoo.com - March 15 at 7:25 AM
Lexaria Bioscience Corp.: Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021Lexaria Bioscience Corp.: Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021
finanznachrichten.de - March 11 at 9:14 AM
Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021
finance.yahoo.com - March 11 at 9:14 AM
Could DehydraTECH(TM) CBD be Worth $3 Billion a Year to Lexaria?Could DehydraTECH(TM) CBD be Worth $3 Billion a Year to Lexaria?
finance.yahoo.com - March 9 at 1:48 PM
Lexaria Bioscience Corp. is Changing the Future of Drug DeliveryLexaria Bioscience Corp. is Changing the Future of Drug Delivery
finance.yahoo.com - March 2 at 11:56 PM
LEXX.OQ - Lexaria Bioscience Corp Profile | ReutersLEXX.OQ - Lexaria Bioscience Corp Profile | Reuters
reuters.com - February 5 at 5:45 PM
Lexaria Bioscience Corp.: Lexaria Provides Guidance on Upcoming R&DLexaria Bioscience Corp.: Lexaria Provides Guidance on Upcoming R&D
finanznachrichten.de - February 2 at 5:24 PM
This page was last updated on 7/25/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.